## Supplementary Information

2	
3	Tetrahydromagnolol induces autophagic cell death by targeting the m <sup>6</sup> A
4	reader protein YTHDF2 and enhances the efficacy of anti-PD-1 immunotherapy
5	in pancreatic cancer cells
6	Guohua Li <sup>1, 2, #</sup> , Qibiao Wu <sup>2, #</sup> , Yiping Mou <sup>3, #</sup> Yunhao Qiao <sup>1, #</sup> , Lijun Jin <sup>4</sup> , Qian Shi <sup>1</sup> , Ruonan
7	Zhang <sup>1</sup> , Jie Li <sup>1, 2</sup> , Yitian Sun <sup>1, 2</sup> , Aili Zhang <sup>1, 2</sup> , Haiyang Jiang <sup>1</sup> , Zijing Yang <sup>1</sup> , Zhiyu Zhu <sup>1</sup> ,
8	Mengmeng Ma <sup>1</sup> , Xiaoyu Sun <sup>1</sup> , Xinbing Sui <sup>1, 2, *</sup>
9	<sup>1</sup> School of Pharmacy, Hangzhou Normal University, Hangzhou, 311121, Zhejiang, China
10	<sup>2</sup> State Key Laboratory of Quality Research in Chinese Medicines, Faculty of Chinese Medicine,
11	Macau University of Science and Technology, Macau, P.R. China
12	<sup>3</sup> Department of Gastrointestinal and Pancreatic Surgery, Zhejiang Provincial People's Hospital,
13	People's Hospital of Hangzhou Medical College, Hangzhou, Zhejiang, China
14	<sup>4</sup> Department of Traditional Chinese Medicine, The Second Affiliated Hospital, School of
15	Medicine, Zhejiang University, Hangzhou, Zhejiang, China
16	
17	
18	*Correspondence: suilab@hznu.edu.cn (X.S.)
19 20	<sup>#</sup> These authors contribute equally.

## 22 Supplementary Figures:



23

Figure S1. THM inhibited cell proliferation and induced cell death in pancreatic cancer cells. 24 (A) MIAPaCa-2, CFAPC-1, Capan1 and Capan2 cells were treated with different 25 concentrations of THM for 24 h, and cell viability was measured by CCK8 assay. (B-C) The 26 quantitative analysis of the colony formation after the treatment with THM, means ±S.D., n = 27 3; \**p* < 0.05, \*\*\**p* < 0.001. (**D-E**) The quantitative analysis of annexin V-FITC/ PI staining after 28 29 the treatment with THM for 24 h, means  $\pm$ S.D., n = 3; \*\*p < 0.01, \*\*\*p < 0.001. (F-G) The quantitative analysis of cell cycle after the treatment with THM for 24 h. (H-I) 30 Immunofluorescence staining for DNA damage marker y-H2AX in SW1990 and PANC-1 cells 31 32 after THM treatment for 24 h.







С

150-

100-

50

Cell viability (%)





SW1990

ns



D













Figure S2. The effect of THM alone or combines with different cell death inhibitors on the cell 35 viability of pancreatic cancer cells. (A) SW1990 and PANC-1 cells were treated with THM with 36 or without Z-VAD (10 µM) for 24 h, and cell viability was detected. (B) SW1990 and PANC-1 37 cells were treated with THM with or without DFO (10 µM) for 24 h, and cell viability was 38 39 detected. (C) SW1990 and PANC-1 cells were treated with THM with or without NAC (1 mM) 40 for 24 h, and cell viability was detected. (D) SW1990 and PANC-1 cells were treated with THM with or without Nec-1 (10 µM) for 24 h, and cell viability was detected. (E) SW1990 and PANC-41 1 cells were treated with THM with or without Baf-A1 (20 nM) for 24 h, and cell viability was 42 detected. (F) SW1990 and PANC-1 cells were treated with THM with or without CQ (25 µM) 43 44 for 24 h, and cell viability was detected. Data are summarized as mean ± S.D., \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001, ns: not significant (n = 3). 45



47

Figure S3. (A-D) ATG5/7 protein in knocked-down SW1990 and PANC-1 cells was analyzed 48 49 by western blot. GAPDH was used as internal control. (E-H) SW1990 and PANC-1 cells were 50 treated with different concentrations of THM for 24 h after knocking down the expression of ATG5/7, and cell viability was measured by CCK8 assay. n = 3; \*\*p < 0.01, \*\*\*p < 0.001. (I-L) 51 ATG5/7 protein in over-expressed SW1990 and PANC-1 cells was analyzed by western blot. 52 GAPDH was used as internal control. (M-P) SW1990 and PANC-1 cells were treated with 53 different concentrations of THM for 24 h after overexpression of ATG5/7, and cell viability was 54 measured by CCK8 assay. n = 3; \*\**p* < 0.01, \*\*\**p* < 0.001. 55



Figure S4. THM suppressed YTHDF2 recognition of m<sup>6</sup>A mRNA targets. (A-B) Analysis of ATG7 mRNA expression in SW1990 and PANC-1 cells by RT-qPCR after overexpression of YTHDF2 with or without THM treatment. n = 3; \*\*\*p < 0.001. (C-F) Analysis of ATG5 and YTHDF2 mRNA expression in SW1990 and PANC-1 cells by RT-qPCR after knockdown of ATG5. n = 3; \*\*p < 0.01. (G-J) Analysis of ATG7 and YTHDF2 mRNA expression in SW1990 and PANC-1 cells by RT-qPCR after knockdown of ATG7. n = 3; \*\*p < 0.01. (K-L) The predicted m<sup>6</sup>A sites of ATG5 and ATG7 mRNA via SRAMP (<u>http://www.cuilab.cn/sramp/</u>). 



Figure S5. Effects of THM on cell viability through YTHDF2 and autophagy regulation in pancreatic cancer cells. (A-B) Analysis of cell viability in SW1990 and PANC-1 cells by CCK8 assay after transfection with shNC or shYTHDF2 and treatment with THM with or without CQ for 24 h. Data are presented as mean  $\pm$  S.D. of three independent experiments. \*\*\**p* < 0.001, ns: not significant.

89

- 96
- 97
- 98



Figure S6. The anticancer activities of THM on pancreatic cancer were evaluated using
xenograft models *in vivo*. (A) After treatment with saline or THM for 10 times, mice serum was
taken for the determination of alanine transaminase (ALT) assay. (B) After treatment with
saline or THM for 10 times, mice serum was taken for aspartate aminotransferase (AST) assay.
(C) After treatment with saline or THM for 10 times, mice serum was taken for creatine kinase
(CK) assay. (D) After treatment with saline or THM for 10 times, mice serum was taken for
urea (UREA) assay. (E) After treatment with saline or THM for 10 times, mice serum was taken

108 for creatinine (CR) assay. All the data are presented as means ±S.D. ns: there was no 109 significant difference.



111

Figure S7. The anticancer activities of THM on pancreatic cancer were evaluated using PDX models *in vivo*. (A) PDX#1 mice serum was taken for the determination of ALT assay in different groups. (B) PDX#1 mice serum was taken for AST assay in different groups. (C)

PDX#1 mice serum was taken for CK assay in different groups. (D) PDX#1 mice serum was taken for CR assay in different groups. (E) PDX#1 mice serum was taken for UREA assay in different groups. (F) PDX#2 mice serum was taken for the determination of ALT assay in different groups. (G) PDX#2 mice serum was taken for aspartate aminotransferase (AST) assay in different groups. (H) PDX#2 mice serum was taken for CK assay in different groups. (I) PDX#2 mice serum was taken for CR assay in different groups. (J) PDX#2 mice serum was taken for UREA assay in different groups. All the data are presented as means ±S.D. ns: there was no significant difference. 



Figure S8. Effects of THM and anti-PD-1 combination therapy on immune cell infiltration in pancreatic cancer. (A-C) Quantitative analysis of immunohistochemical staining for CD4, CD8a and PD-1 in orthotopic Pan02-Luc pancreatic cancer tumor sections. Data are summarized as mean  $\pm$  S.D., \*\*\*p < 0.001, ns: not significant (n = 4).



**Figure S9.** Effects of THM on PD-L1/PD-1 expression in pancreatic cancer cells *via* the YTHDF2 signaling pathway. **(A)** SW1990 and PANC-1 cells were treated with different concentrations of THM for 24 h, and PD-L1 protein levels were detected by western blot. **(B)** SW1990 and PANC-1 cells with stable shNC or shYTHDF2 were treated with THM for 24 h, and PD-L1 and YTHDF2 protein levels were detected by western blot.